CMS cuts funding for marketplace navigators for 2nd consecutive year

CMS announced it will cut funding to the healthcare marketplace Navigator Program to $10 million starting in the fall of 2018, representing a sharp decrease. The program helps consumers, small businesses and employees navigate marketplaces, which were created under the Affordable Care Act (ACA) and will conduct a sixth open enrollment period later in 2018.

The program received $36 million in 2017 and $63 million in 2016.

CMS stated it does not need to spend as much on marketing now that the marketplace is more established, pointing to high enrollment numbers last year. Insurers are also spending more in marketing to promote the individual exchanges.

“It’s time for the Navigator program to evolve, which is why we are announcing a new direction for the program today,” CMS Administrator Seema Verma said in a statement. “This decision reflects CMS’ commitment to put federal dollars for the federally-facilitated Exchanges to their most cost-effective use in order to better support consumers through the enrollment process.”

Critics argue the move is another attempt to destabilize insurance markets, following repeated attempts by Republicans to overturn the ACA.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.